

New Choices in Targeted Treatments for Advanced or Metastatic Urothelial Carcinoma
Tweetorial #1 References: Adjuvant Therapy

Tweet 4

Nadal R, Apolo AB. Overview of current and future adjuvant therapy for muscle-invasive urothelial carcinoma. *Curr Treat Options Oncol*. 2018;19:36. <https://doi.org/10.1007/s11864-018-0551-z>

Massari F, Santoni M, di Nunno V, et al. Adjuvant and neoadjuvant approaches for urothelial cancer: Updated indications and controversies. *Cancer Treat Rev*. 2018;68:80-85. <https://doi.org/10.1016/j.ctrv.2018.06.002>

Tweet 5

Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. *Urology*. 2007;69:62-79. <https://doi.org/10.1016/j.urology.2006.10.041>

Pederzoli F, Bandini M, Briganti A, et al. Incremental utility of adjuvant chemotherapy in muscle-invasive bladder cancer: quantifying the relapse risk associated with therapeutic effect. *Eur Urol*. 2019;76:425-429. <https://doi.org/10.1016/j.eururo.2019.06.032>

Tweet 6

Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. *Urology*. 2007;69:62-79. <https://doi.org/10.1016/j.urology.2006.10.041>

Tweet 8

Birtle A, Johnson M, Chester J, et al. Adjuvant chemotherapy in upper tract urothelial carcinoma (the POUT trial): a phase 3, open-label, randomised controlled trial. *The Lancet*. 2020; 395:1267-1277. [https://doi.org/10.1016/S0140-6736\(20\)30415-3](https://doi.org/10.1016/S0140-6736(20)30415-3)

Tweet 9

Sternberg CN, Donat SM, Bellmunt J, et al. Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer. *Urology*. 2007;69:62-79. <https://doi.org/10.1016/j.urology.2006.10.041>

Tweet 11

Wallis CJD. ASCO GU 2021: First results from the phase 3 Checkmate 274 trial of adjuvant nivolumab vs placebo in patients who underwent radical surgery for high-risk muscle-invasive urothelial carcinoma. Presented at 2021 American Society of Clinical Oncology Genitourinary Cancers Symposium; February 11th-February 13th, 2021; Virtual.

Tweet 12

Bellmunt J, Hussain PM, Gschwend JE, et al. Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial. *The Lancet Oncology*. 2021;22:525-537. [https://doi.org/10.1016/S1470-2045\(21\)00004-8](https://doi.org/10.1016/S1470-2045(21)00004-8)

Tweet 14

Kadow B. ASCO GU 2019: Pembrolizumab in muscle-invasive and locally advanced urothelial carcinoma - AMBASSADOR versus observation. Presented at 2019 American Society of Clinical Oncology Genitourinary Cancers Symposium; February 14-16, 2019; San Francisco, CA.

Pal SK, Daneshmand S, Matin SF, et al. PROOF 302: A randomized, double-blind, placebo-controlled, phase III trial of infigratinib as adjuvant therapy in patients with invasive urothelial carcinoma harboring FGFR3 alterations. *J Clin Oncol*. 2020;38:6. https://doi.org/10.1200/JCO.2020.38.6_suppl.TPS600

Glossary

b/f, before
chemo, chemotherapy
CHT, chemotherapy
CI, confidence interval
DFS, disease-free survival
Dz, disease
ECOG, Eastern Cooperative Oncology Group
Feat., features
FGFR3, fibroblast growth factor receptor 3
FGFR1-3, fibroblast growth factor receptor 1
HR, hazard ratio
ICI, immune checkpoint inhibitors
ITT, intent-to-treat population
m, month
M0, nonmetastasized stage
MIUC, muscle-invasive urothelial carcinoma
NIVO, nivolumab
PBO, placebo
PD-1, programmed death-1
PD-L1, programmed death-ligand 1
Ph, phase
pN+, tumor-specific stages
pts, patients
Pt, platinum
pT3, urothelial carcinoma subtype
pT3-pT4a, problematic issue in Tn stage
RC, radical cystectomy
RCT, randomized controlled trial
RISC, RNA-induced silencing complex
RT, radiation therapy
T3, cancer stage
T4, cancer stage
Tn, T antigen nouvelle
TRAE, treatment-related adverse event
Tx, treatment
UC, urothelial carcinoma
UTUC, upper tract urothelial carcinoma
ypN+, tumor-specific stages
ypT2-4a, tumor-specific stages
yr, year